Likewise, wild-type p53 levels were dramatically increased after USP7 inhibitor P5091 treatment (Figure 5A), while mutant p53 levels were decreased in cancer cell endogenously expressing mutant p53 (Figures 5B–E). Here, USP7 is linked to cancer.